In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.
The Life Raft Group is pleased to present the members of the LRG 2021 Medical Advisory Board. Members will play a crucial role in offering expert opinions on research and medical developments.
In this issue of LRG Science, we highlight the power of collaboration in medicine with a recap of the Virtual Tumor Board co-hosted with the NIH. Due to the pandemic, The Life Raft Group was asked to organize a Virtual Tumor Board to assure that challenging cases were presented in order to help the patients and their treating physicians develop an effective treatment plan.
In this issue of LRG Science, we release breaking news of our newest collaboration - with OHSU on the GIST Collaborative Tissue Bank. The LRG has a unique patient registry with over 2,000 members and this collaboration is an important example of the vital role patient advocacy groups and academic institutions play in bridging the gap between researchers and motivated patient populations who want to share their clinical histories and tissue to create new treatments and better outcomes.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing email@example.com with the subject line SUBSCRIBE LRG SCIENCE.
The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing firstname.lastname@example.org with the subject line SUBSCRIBE LRG SCIENCE.
PDF is available of LRG Science to print here. An oncologist in Chennai, India, 8,366 miles away from the Life Raft Group’s Wayne, New Jersey office, is running out of treatment [...]
PDF is available of LRG Science to print here. Real World Evidence in Action Although targeted medicine has brought about immense progress in cancer treatment, there are still enormous challenges [...]